These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 23174439)

  • 1. Are there different neural mechanisms responsible for three stages of weight gain development in anti-psychotic therapy: temporally based hypothesis.
    Pai N; Deng C; Vella SL; Castle D; Huang XF
    Asian J Psychiatr; 2012 Dec; 5(4):315-8. PubMed ID: 23174439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TNF-α -308 G>A polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment.
    Huang HH; Wang YC; Wu CL; Hong CJ; Bai YM; Tsai SJ; Liou YJ
    Neurosci Lett; 2011 Oct; 504(3):277-80. PubMed ID: 21967963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course.
    Gebhardt S; Haberhausen M; Heinzel-Gutenbrunner M; Gebhardt N; Remschmidt H; Krieg JC; Hebebrand J; Theisen FM
    J Psychiatr Res; 2009 Mar; 43(6):620-6. PubMed ID: 19110264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents.
    Fleischhaker C; Heiser P; Hennighausen K; Herpertz-Dahlmann B; Holtkamp K; Mehler-Wex C; Rauh R; Remschmidt H; Schulz E; Warnke A
    J Neural Transm (Vienna); 2007 Feb; 114(2):273-80. PubMed ID: 17109073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weight gain associated with antipsychotic drugs.
    Ganguli R
    J Clin Psychiatry; 1999; 60 Suppl 21():20-4. PubMed ID: 10548138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate.
    Lin YH; Liu CY; Hsiao MC
    Psychiatry Clin Neurosci; 2005 Oct; 59(5):613-5. PubMed ID: 16194268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
    Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach.
    Castro-Fornieles J; Parellada M; Soutullo CA; Baeza I; Gonzalez-Pinto A; Graell M; Paya B; Moreno D; de la Serna E; Arango C
    J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):327-36. PubMed ID: 18759642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain?
    Vieweg WV; Sood AB; Pandurangi A; Silverman JJ
    Acta Psychiatr Scand; 2005 Mar; 111(3):177-84. PubMed ID: 15701101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel antipsychotics: comparison of weight gain liabilities.
    Wirshing DA; Wirshing WC; Kysar L; Berisford MA; Goldstein D; Pashdag J; Mintz J; Marder SR
    J Clin Psychiatry; 1999 Jun; 60(6):358-63. PubMed ID: 10401912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.
    Moreno C; Merchán-Naranjo J; Alvarez M; Baeza I; Alda JA; Martínez-Cantarero C; Parellada M; Sánchez B; de la Serna E; Giráldez M; Arango C
    Bipolar Disord; 2010 Mar; 12(2):172-84. PubMed ID: 20402710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
    Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical antipsychotics: new drugs, new challenges.
    Mathews M; Muzina DJ
    Cleve Clin J Med; 2007 Aug; 74(8):597-606. PubMed ID: 17708131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population.
    Perez-Iglesias R; Crespo-Facorro B; Martinez-Garcia O; Ramirez-Bonilla ML; Alvarez-Jimenez M; Pelayo-Teran JM; Garcia-Unzueta MT; Amado JA; Vazquez-Barquero JL
    Schizophr Res; 2008 Feb; 99(1-3):13-22. PubMed ID: 18053689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.
    Sikich L; Hamer RM; Bashford RA; Sheitman BB; Lieberman JA
    Neuropsychopharmacology; 2004 Jan; 29(1):133-45. PubMed ID: 14583740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mechanisms of the body weight gain induced by novel antipsychotic drugs and concomitant lipid abnormalities].
    Kostulski A; Wyszogrodzka-Kucharska A; Rabe-Jabłońska J
    Przegl Lek; 2005; 62(9):938-43. PubMed ID: 16541734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychotic disorders, eating habits, and physical activity: who is ready for lifestyle changes?
    Archie SM; Goldberg JO; Akhtar-Danesh N; Landeen J; McColl L; McNiven J
    Psychiatr Serv; 2007 Feb; 58(2):233-9. PubMed ID: 17287381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications.
    Lasser RA; Mao L; Gharabawi G
    Schizophr Res; 2004 Feb; 66(2-3):163-7. PubMed ID: 15061249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weight gain: side effect of atypical neuroleptics?
    Wetterling T; Müssigbrodt HE
    J Clin Psychopharmacol; 1999 Aug; 19(4):316-21. PubMed ID: 10440458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors.
    Pérez-Iglesias R; Martínez-García O; Pardo-Garcia G; Amado JA; Garcia-Unzueta MT; Tabares-Seisdedos R; Crespo-Facorro B
    Int J Neuropsychopharmacol; 2014 Jan; 17(1):41-51. PubMed ID: 24103107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.